EGFR and non-small cell lung carcinoma: Activating EGFR mutations (e.g., exon 19 deletions and L858R) are predictive of progression-free survival (PFS), overall survival (OS), and response to tyrosine kinase inhibitors (TKIs) [4], of which afatinib, gefitinib, and erlotinib have been approved to treat EGFR-mutated NSCLC [4–6].